Tx 45 yo w/ 0.8-cm node-neg, ER-neg/HER2+ early BC? Tx 70 yo w/ 1 pos node, ER-neg/HER2+ early BC?
Which systemic treatment do you generally use for a 45-year-old patient with node-negative, ER-negative, HER2-positive early breast cancer with a 0.8-cm tumor?
Which systemic treatment do you generally use for a 70-year-old woman with ER-negative, HER2-positive early breast cancer and 1 positive node?
A phase II trial of adjuvant paclitaxel and trastuzumab for node-negative HER2-positive breast cancer. NCT00542451
Burstein H et al. Choosing the best trastuzumab-based adjuvant chemotherapy regimen: Should we abandon anthracyclines? J Clin Oncol 2012;30(18):2179-82. Abstract
Jones SE et al. Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: A single-group, open-label, phase 2 study. Lancet Oncol 2013;[Epub ahead of print]. Abstract
Phase III trial of doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel with or without trastuzumab as adjuvant treatment for women with HER-2 overexpressing node positive or high-risk node negative breast cancer. NCT00005970
Slamon D et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011;365(14):1273-83. Abstract